

Special Issue

Gynecological Oncology: Personalized Diagnosis and Therapy

Message from the Guest Editors

The treatment of gynaecological cancers has, in recent years, seen a transformation away from universal radical extirpative surgery, non-conformal radiotherapy techniques, and a default reliance on platinum-based chemotherapy agents to a wide range of precision medical and surgical interventions, individually targeting both the patient and their cancer. From vaccination and screening for cervical dysplasia and cancer through HPV DNA and RNA techniques to informing drug therapies and prophylactic surgery in endometrial cancer and ovarian cancer, genomic medicine is driving the personalisation of targeted cancer prevention and treatments. This Special Issue welcomes submissions that contain original research in the translational and clinical domains or review articles that demonstrate innovation towards the personalisation of gynaecological cancer detection, prevention, and treatment across surgical, radiation, and medical oncology fields and palliative medicine.

Guest Editors

Dr. Stuart Rundle

Department of Gynaecological Oncology, Queen Elizabeth Hospital,
Gateshead NE9 6SX, UK

Dr. Ali Kucukmetin

Northern Gynaecological Oncology Centre, Queen Elizabeth Hospital,
Gateshead NE9 6SX, UK

Deadline for manuscript submissions

25 June 2026



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/204707

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).